Literature DB >> 15908507

A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.

Emma C Morris1, Aristotle Tsallios, Gavin M Bendle, Shao-An Xue, Hans J Stauss.   

Abstract

Adoptive transfer of antigen-specific CD4(+) and CD8(+) T cells is one of the most efficient forms of cancer immunotherapy. However, the isolation of antigen-specific CD4(+) T cells is limited because only few tumor-associated helper epitopes are identified. Here, we used T cell antigen receptor gene transfer to target CD4(+) T cells against an MHC class I-presented epitope of a model tumor antigen. IFN-gamma-producing CD4(+) T cells were unable to expand in vivo and to provide help for tumor rejection. In contrast, CD4(+) T cells producing high levels of IL-2 expanded in vivo, provided help for cytotoxic T lymphocyte-mediated tumor rejection, and developed T cell memory. The data demonstrate in vivo synergy between T cell antigen receptor-transduced CD4(+) and CD8(+) T cells specific for the same epitope resulting in long-term tumor protection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908507      PMCID: PMC1142362          DOI: 10.1073/pnas.0500357102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis.

Authors:  Arno Müllbacher; Mario Lobigs; Ron Tha Hla; Thao Tran; Thomas Stehle; Markus M Simon
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

3.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

Authors:  Karl S Peggs; Stephanie Verfuerth; Arnold Pizzey; Naeem Khan; Malcolm Guiver; Paul A Moss; Stephen Mackinnon
Journal:  Lancet       Date:  2003-10-25       Impact factor: 79.321

4.  Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication.

Authors:  B E Palmer; E Boritz; N Blyveis; C C Wilson
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

6.  Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.

Authors:  Tanzina Haque; Gwen M Wilkie; Clare Taylor; Peter L Amlot; Parvez Murad; Angela Iley; Dilani Dombagoda; Kate M Britton; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Lancet       Date:  2002-08-10       Impact factor: 79.321

7.  Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.

Authors:  Niels Schaft; Ralph A Willemsen; Jolanda de Vries; Birgit Lankiewicz; Bram W L Essers; Jan-Willem Gratama; Carl G Figdor; Reinier L H Bolhuis; Reno Debets; Gosse J Adema
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

8.  High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Authors:  Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

9.  Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity.

Authors:  R J Orentas; L A Bircher; S Roskopf
Journal:  Scand J Immunol       Date:  2003-07       Impact factor: 3.487

10.  Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.

Authors:  Hiroyuki Tahara; Keishi Fujio; Yasuto Araki; Keigo Setoguchi; Yoshikata Misaki; Toshio Kitamura; Kazuhiko Yamamoto
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

View more
  42 in total

1.  Cancer immunotherapy: in vivo imaging of adoptively transferred T cells in an immunocompetent host.

Authors:  Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-29       Impact factor: 11.205

Review 2.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

3.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Authors:  Ralf-Holger Voss; Jürgen Kuball; Renate Engel; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

5.  Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Authors:  Raquel Gomez-Eerland; Bastiaan Nuijen; Bianca Heemskerk; Nienke van Rooij; Joost H van den Berg; Jos H Beijnen; Wolfgang Uckert; Pia Kvistborg; Ton N Schumacher; John B A G Haanen; Annelies Jorritsma
Journal:  Hum Gene Ther Methods       Date:  2014-09-22       Impact factor: 2.396

6.  TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice.

Authors:  Inez Johanna; Patricia Hernández-López; Sabine Heijhuurs; Laura Bongiovanni; Alain de Bruin; Dennis Beringer; Sanne van Dooremalen; Leonard D Shultz; Fumihiko Ishikawa; Zsolt Sebestyen; Trudy Straetemans; Jürgen Kuball
Journal:  J Leukoc Biol       Date:  2020-02-05       Impact factor: 4.962

7.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

8.  Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+)  CD25(-) and CD8(+) T cells attenuates effector function.

Authors:  Sidharth S Jha; Nitya G Chakraborty; Prashant Singh; Bijay Mukherji; David I Dorsky
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

Review 9.  T cell receptor gene therapy for cancer.

Authors:  Thomas M Schmitt; Gunnar B Ragnarsson; Philip D Greenberg
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

10.  TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

Authors:  Moniek A de Witte; Gavin M Bendle; Marly D van den Boom; Miriam Coccoris; Todd D Schell; Satvir S Tevethia; Harm van Tinteren; Elly M Mesman; Ji-Ying Song; Ton N M Schumacher
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.